Trim 25-30% of MO in resistance zone; Underweight rating captures structural deterioration without liquidating working defensive bid
Underweight rating reflects 25-30% trim recommendation at current resistance levels ($69.50-$70.50), justified by structural deterioration (operating income compression from $11.92B in 2022 to $9.90B in 2025, $2.1B in write-offs, hawkish Fed regime, competitive erosion from PM's Zyn and BTI's Velo/Kodiak) while bounded from below by the Conservative's countervailing points (FCF durability $8.05-$9.29B annually, buyback lever as backstop, defensive bid validated September 16, 200 SMA structural floor intact, 6.3% dividend with 61-year streak). The Underweight rating captures the asymmetric downside without liquidating into a working defensive bid—the income floor and dividend coverage remain structurally intact, but the contested pivot has not resolved and operating trajectory continues to compress.
| Position | Action |
|---|---|
| Trim 25-30% of total MO position in resistance zone | Execute via two tranches |
| First tranche: half of trim in $69.80-$70.30 range | Execute over next 1-2 sessions |
| Second tranche: remaining half at $70.50 or RSI >65 | Execute on price target or momentum signal |
| Residual position daily close below $66.50 | Hard stop triggered (below 200 SMA with buffer) |
Altria is a defensive cash compounder with elite profitability metrics and sustainable 6.3% yield, benefiting from hawkish Fed tailwinds and smoke-free optionality, making it a buy on dips to $67.60-$68.29.
| Indicator | Value | Signal |
|---|---|---|
| 10 EMA | 68.56 | bullish |
| 50 SMA | 68.29 | bullish |
| 200 SMA | 64.60 | bullish |
| RSI | 61.41 | neutral |
| MACD | 0.50 | bullish |
| MACD Signal | 0.11 | bullish |
| MACD Histogram | 0.39 | bullish |
| Bollinger Upper | 70.34 | neutral |
| Bollinger Middle | 67.60 | neutral |
| Bollinger Lower | 64.86 | neutral |
| ATR | 1.50 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: $70.50 price level OR RSI >65
Then: Trim remaining 12.5-15% of position
Pricing power offsets volume decline, producing rising gross profit and sustainable free cash flow
↩ rebuts: “Bear's 'Dividend Paradox' thesis that raising dividend while volume declines is unsustainable”
EV: $72–$73 (from breakout above $70.34) · concedes: Short-term mean reversion risk exists while pressing upper Bollinger Band at $70.34; Mix dilution from Basic/discount brands is a watch item; PM's smoke-free story (Zyn, IQOS) is genuinely strong; BTI has international exposure though with currency risk
MO is a structurally declining business trading at technical resistance after a momentum chase, with a dividend that consumes nearly all free cash flow against a deteriorating balance sheet, negative book value, and compounding headwinds from the smoke-free pivot's capital destruction, macro headwinds, and regulatory risk.
EV: -$5.00 to -$7.00 (downside targets to $65.50-$63.00)
→ vs conservative: Yield-at-all-costs thesis ignores 17% operating income deterioration and dividend coverage math that uses flat interest expense and zero growth capex rather than realistic debt servicing and NJOY/Helix defense spending
→ vs conservative: Defensive beta (0.494) offers no shield when hawkish Fed pushes 10-year toward 5.25-5.5% and compresses MO's 130bp yield premium, triggering multiple contraction alongside the bond market
→ vs conservative: Dividend King narrative anchors on 50-plus years of raises while ignoring that payout ratio is becoming structurally unsupportable against declining operating income
→ vs neutral: Wait-and-see approach misses that clarity arrives after the multiple has already moved; trim into strength at resistance ($69.50-$70.50) rather than selling a failed breakout at $68.29
→ vs neutral: M&A optionality from Polymarket odds (40-43%) is upside for niche pouch brand sellers, not MO as acquirer where capex and integration risk compound existing $2.1B in impairments and write-offs
→ vs neutral: Subtle warning framing understates BTI's Velo/Kodiak share gains and PM's Zyn dominance; competitive erosion in smokeless is structural, not cyclical
| VWMA | 68.18 | bullish |
| Current Close | 70.10 | bullish |
Support: 68.56 · 68.29 · 67.6 · 64.86 · 64.6 · 62.95 · 52.81 | Resistance: 70.34 · 72 · 73
MO is in a strong bullish technical setup with price stacked above all three moving averages and a fresh MACD bullish crossover. RSI at 61.41 offers room for further upside before reaching overbought territory. Key resistance sits at 70.34 (upper Bollinger Band), with support zones at 68.29 (50 SMA) and 67.60 (20 SMA), while a stop-loss near $68.10 is recommended for trend-following entries with a target of $72-$73.
Market Cap
$117.05 B
PE Ratio (TTM)
14.76
Forward PE
11.95
PEG Ratio
2.64
Price/Book
-43.87
EPS (TTM)
$4.75
Forward EPS
$5.86
Beta
0.494
52-Week High
$77.06
52-Week Low
$54.70
50-Day MA
$69.40
200-Day MA
$66.71
Revenue (2025)
$20,139 million
Gross Profit (2025)
$14,542 million
Operating Income (2025)
$9,899 million
Net Income (2025)
$6,947 million
Diluted EPS (2025)
$4.12
EBITDA (2025)
$10,832 million
Revenue (TTM)
$20.44 B
Gross Profit
$17.79 B
EBITDA
$15.74 B
Net Income
$7.95 B
Operating Margin
76.1%
Profit Margin
39.0%
ROA
29.5%
Gross Margin
~72%
Current Ratio
0.518
Cash
$4.47 B
Total Assets
$35,017 million
Total Debt
$25.71 B
Long-Term Debt
$24,140 million
Net Debt
$21.24 B
Net Debt/EBITDA
~1.96x
Stockholders' Equity
($3,502 million)
Treasury Stock
$43,183 million
Goodwill & Intangibles
$17,663 million
Operating Cash Flow (2025)
$9,290 million
Free Cash Flow
$9.01 B
FCF Yield
~7.7%
CapEx (2025)
$216 million
Dividends Paid (2025)
$6.96 B
Buybacks (2025)
$1.00 B
Debt Repaid (2025)
$1,607 million
Dividend Coverage
~1.3x
Strengths
Concerns
Altria Group operates a near-monopoly in U.S. tobacco with Marlboro as the world's most valuable cigarette brand, generating ~72% gross margins and $9B+ annual free cash flow from a asset-light model. The stock trades at 11.95x forward earnings with 23% implied EPS growth and a 7.7% FCF yield, while returning ~$8B annually to shareholders through dividends and buybacks. Key risks include structural volume declines, regulatory headwinds (FDA menthol actions), litigation exposure, and $25.7B in debt; however, the company's pricing power, dominant market position, and 50+ year dividend growth history make it ideal for income and defensive investors seeking steady capital returns.
Macro: The Federal Reserve delivered a hawkish surprise on September 16, 2026, raising rates (not cutting) and causing the Dow to sink ~600 points; Polymarket implies 95% probability of zero rate cuts in 2026 with 10-year Treasury yields rising just below 5%. JPMorgan CEO Jamie Dimon publicly questioned whether inflation has been 'slayed.' Recession odds remain low at 12% (+4pp WoW) but creeping higher. Against this backdrop, MO's ~6.3% yield sits ~130bps above the 10-year Treasury — the widest premium in years — making the stock attractive as a defensive income play.